Overview

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Radiation Therapy Oncology Group

Collaborators:

National Cancer Institute (NCI)
NRG Oncology

Treatments:

Androgens
Bicalutamide
Buserelin
Flutamide
Goserelin
Leuprolide
Triptorelin Pamoate